Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial by Ailani, Jessica, Lipton, Richard B., Hutchinson, Susan, Knievel, Kerry, Lu, Kaifeng, Butler, Matthew, Yu, Sung Yun, Finnegan, Michelle, Severt, Lawrence, Trugman, Joel M.

Get full text

Neuroimaging Markers of Motor and Nonmotor Features of Parkinson's Disease: An [18F]Fluorodeoxyglucose Positron Emission Computed Tomography Study by Huang, Chaorui, Ravdin, Lisa D., Nirenberg, Melissa J., Piboolnurak, Panida, Severt, Lawrence, Maniscalco, James S., Solnes, Lilja, Dorfman, Benjamin J., Henchcliffe, Claire

Get full text

It's tricky: Rating alleviating maneuvers in cervical dystonia by Cisneros, Elizabeth, Stebbins, Glenn T., Chen, Qiyu, Vu, Jeanne P., Benadof, Casey N., Zhang, Zheng, Barbano, Richard L., Fox, Susan H., Goetz, Christopher G., Jankovic, Joseph, Jinnah, Hyder A., Perlmutter, Joel S., Adler, Charles H., Factor, Stewart A., Reich, Stephen G., Rodriguez, Ramon, Severt, Lawrence L., Stover, Natividad P., Berman, Brian D., Comella, Cynthia L., Peterson, David A.

Get full text

Pathophysiology and treatment of alien hand syndrome by Sarva, Harini, Deik, Andres, Severt, William Lawrence

Get full text

Disease Modification in Parkinson’s Disease by Henchcliffe, Claire, Severt, W. Lawrence

Get full text

Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial by Pozo-Rosich, Patricia, Ailani, Jessica, Ashina, Messoud, Goadsby, Peter J, Lipton, Richard B, Reuter, Uwe, Guo, Hua, Schwefel, Brittany, Lu, Kaifeng, Boinpally, Ramesh, Miceli, Rosa, De Abreu Ferreira, Rosa, McCusker, Emily, Yu, Sung Yun, Severt, Lawrence, Finnegan, Michelle, Trugman, Joel M

Get full text

Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II by Hutchinson, Susan, Silberstein, Stephen D, Blumenfeld, Andrew M, Lipton, Richard B, Lu, Kaifeng, Yu, Sung Yun, Severt, Lawrence

Request full text

Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial by Schwedt, Todd J, Lipton, Richard B, Ailani, Jessica, Silberstein, Stephen D, Tassorelli, Cristina, Guo, Hua, Lu, Kaifeng, Dabruzzo, Brett, Miceli, Rosa, Severt, Lawrence, Finnegan, Michelle, Trugman, Joel M

Get full text

Mysticol: A controlled study of myobloc in the treatment of sialorrhea in Parkinson's disease (PD) and other neurological conditions by Isaacson, Stuart, Severt, Lawrence, Clinch, Thomas

Get full text

Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial by Ashina, Messoud, Tepper, Stewart J., Reuter, Uwe, Blumenfeld, Andrew M., Hutchinson, Susan, Xia, Jing, Miceli, Rosa, Severt, Lawrence, Finnegan, Michelle, Trugman, Joel M.

Get full text

Ubrogepant for the acute treatment of migraine when administred during the prodrome: Results from a phase 3, randomized, double-blind, placebo-controlled, crossover study by Dodick, David, Goadsby, Peter, Schwedt, Todd, Lipton, Richard, Davidovic, Goran, Liu, Chengcheng, Lu, Kaifeng, Yun, Yu Sung, Severt, Lawrence, Finnegan, Michelle, Trugman, Joel

Get full text

Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectiona... by Simuni, Tanya, Uribe, Liz, Caspell-Garcia, Chelsea, Coffey, Christopher S, Siderowf, Andrew, Trojanowski, John Q, Shaw, Leslie M, Seibyl, John, Toga, Arthur W, Galasko, Doug, Tosun, Duygu, Poston, Kathleen, Weintraub, Daniel, Mollenhauer, Brit, Tanner, Caroline M, Kieburtz, Karl, Hutten, Samantha J, Bressman, Susan, Marek, Kenneth, Chowdhury, Sohini, Sherer, Todd, Casaceli, Cynthia, Dorsey, Ray, Wilson, Renee, Mahes, Sugi, Salerno, Christina, Crawford, Karen, Casalin, Paola, Malferrari, Giulia, Weisz, Mali Gani, Orr-Urtreger, Avi, Montine, Thomas, Baglieri, Chris, Russell, David, Giladi, Nir, Factor, Stewart, Hauser, Robert, Jankovic, Joseph, Saint-Hilaire, Marie, Richard, Irene, Shprecher, David, Brockmann, Katrina, Barone, Paolo, Espay, Alberto, Santiago, Anthony, Hu, Shu-Ching, Isaacson, Stuart, Corvol, Jean-Christophe, Ruiz Martinez, Javiar, Tolosa, Eduardo, Tai, Yen, Smejdir, Debra, Rees, Linda, Williams, Karen, Kausar, Farah, Richardson, Whitney, Willeke, Diana, Peacock, Shawnees, Sommerfeld, Barbara, Freed, Alison, Guthrie, Stephanie, Harrell, Leigh, Thomas, Cathi-Ann, James, Raymond, Zimmerman, Grace, Mule, Jennifer, Hilt, Ella, Ribb, Kori, Ainscough, Susan, Ranola, Madelaine, Mejia Santana, Helen, Moreno, Juliana, Raymond, Deborah, Carvajal, Lisbeth, Carvalo, Stephanie, Croitoru, Ioana, Garrido, Alicia, Payne, Laura Marie, Viswanth, Veena, Severt, Lawrence, Facheris, Maurizio, Cedarbaum, Jesse, Taylor, Peggy, Haider Sheikh, Zulfiqar, Fischer, Tanya, Sardi, Pablo, Forrat, Remi, Reith, Alastair, Ahlberg Hillert, Gabrielle, Saba, Barbara, Min, Chris, Umek, Robert, Mather, Joe, De Santi, Susan, Post, Anke, Boess, Frank, Taylor, Kirsten, Grachev, Igor, Muglia, Pierandrea, Merchant, Kaplana

Get full text

Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults by Goadsby, Peter J, Tepper, Stewart J, Watkins, Paul B, Ayele, Girma, Miceli, Rosa, Butler, Matthew, Severt, Lawrence, Finnegan, Michelle, Szegedi, Armin, Trugman, Joel M, Jakate, Abhijeet

Get full text

Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA by Dodick, David W, Goadsby, Peter J, Schwedt, Todd J, Lipton, Richard B, Liu, Chengcheng, Lu, Kaifeng, Yu, Sung Yun, Severt, Lawrence, Finnegan, Michelle, Trugman, Joel M

Get full text

Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial by Klein, Brad C, Miceli, Rosa, Severt, Lawrence, McAllister, Peter, Mechtler, Laszlo, McVige, Jennifer, Diamond, Merle, Marmura, Michael J, Guo, Hua, Finnegan, Michelle, Trugman, Joel M

Get full text

Nonsteroidal Anti‐inflammatory Use and LRRK2 Parkinson's Disease Penetrance by San Luciano, Marta, Tanner, Caroline M., Meng, Cheryl, Marras, Connie, Lang, Anthony E., Schüle, Birgitt, Langston, J. William, Corvol, Jean‐Christophe, Goldwurm, Stefano, Berg, Daniela, Tazir, Meriem, Mellick, George D., Sue, Carolyn M., Tan, Eng King, Bressman, Susan, Saunders‐Pullman, Rachel, Raymond, Deborah, Barrett, Matthew James, Cabassa, Jose, Groves, Mark, Hunt, Ann L, Lubarr, Naomi, Palmese, Christina, Sachdev, Rivka, Sarva, Harini, Shanker, Vicki, Swan, Matthew Carrington, Soto‐Valencia, Jeannie, Johannes, Brooke, Ortega, Robert, Alcalay, Roy N, Tang, Ming‐X, Santana, Helen Mejia, Orbe‐Reilly, Martha, Fahn, Stanley, Cote, Lucien, Ford, Blair, Louis, Elan, Levy, Oren, Rosado, Llency, Ruiz, Diana, Clark, Lorraine, Marder, Karen S, Corvol, Jean‐Christophe, Bonnet, Anne‐Marie, Welter, Marie‐Laure, Mesnage, Valerie, Vidailhet, Marie, Roze, Emmanuel, Lacomblez, Lucette, Grabli, David, Mart i Masso, Jose Felix, Mondragon Rezola, Elisabet, Alustiza, Ainara Estanga, Pagola, Ana Gorostidi, Pont‐Sunyer, Claustre, Rolan, Dolores Vilas, Fernandez‐Santiago, Ruben, Quintana, Maria, Maragall, Laura, Hentati, Faycal, Farrer, Matthew, Duda, John, Read, Matt, Gibson, Rachel, Sassi, Samia Ben, Zouari, Mourad, Nabli, Fatma, Aasly, Jan, Andersen, Sigrid, Bertoni, John, Carter, Julie, Elmer, Lawrence, Jimenez, Nestor Galvez, Martin, Wayne, Pahwa, Rajesh, Lyons, Kelly, Reich, Stephen, Ramos, Carmen Serrano, Wojcieszek, Joanne, Gurevich, Tanya, Shira, Anat Bar, Weisz, Mali Gana, Yasinovsky, Kira, Zalis, Maayan, Thaler, Avner, Orr‐Urtreger, Avi, Giladi, Nir, Mountain, Joanna, Mestre, Tiago, Ghate, Taneera, Singerman, Jennifer, Al Dakheel, Amaal, Connolly, Barbara S, Gasser, Thomas, Brockmann, Kathrin, Mullins, Meghan E, Northover, Carrie, Facheris, Maurizio, Fiske, Brian

Get full text

Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials by Blumenfeld, Andrew M., Knievel, Kerry, Manack Adams, Aubrey, Severt, Lawrence, Butler, Matthew, Lai, Hongxin, Dodick, David W.

Get full text

Parkinson disease phenotype in Ashkenazi jews with and without LRRK2 G2019S mutations by Alcalay, Roy N., Mirelman, Anat, Saunders-Pullman, Rachel, Tang, Ming-X, Mejia Santana, Helen, Raymond, Deborah, Roos, Ernest, Orbe-Reilly, Martha, Gurevich, Tanya, Bar Shira, Anat, Gana Weisz, Mali, Yasinovsky, Kira, Zalis, Maayan, Thaler, Avner, Deik, Andres, Barrett, Matthew James, Cabassa, Jose, Groves, Mark, Hunt, Ann L., Lubarr, Naomi, San Luciano, Marta, Miravite, Joan, Palmese, Christina, Sachdev, Rivka, Sarva, Harini, Severt, Lawrence, Shanker, Vicki, Swan, Matthew Carrington, Soto-Valencia, Jeannie, Johannes, Brooke, Ortega, Robert, Fahn, Stanley, Cote, Lucien, Waters, Cheryl, Mazzoni, Pietro, Ford, Blair, Louis, Elan, Levy, Oren, Rosado, Llency, Ruiz, Diana, Dorovski, Tsvyatko, Pauciulo, Michael, Nichols, William, Orr-Urtreger, Avi, Ozelius, Laurie, Clark, Lorraine, Giladi, Nir, Bressman, Susan, Marder, Karen S.

Get full text

Validity of spiral analysis in early Parkinson's disease by Saunders-Pullman, Rachel, Derby, Carol, Stanley, Kaili, Floyd, Alicia, Bressman, Susan, Lipton, Richard B., Deligtisch, Amanda, Severt, Lawrence, Yu, Qiping, Kurtis, Mónica, Pullman, Seth L.

Get full text

Fall risk and gait in Parkinson's disease: The role of the LRRK2 G2019S mutation by Mirelman, Anat, Heman, Talia, Yasinovsky, Kira, Thaler, Avner, Gurevich, Tanya, Marder, Karen, Bressman, Susan, Bar-Shira, Anat, Orr-Urtreger, Avi, Giladi, Nir, Hausdorff, Jeffrey M.

Get full text